We are live on ! Find out more
AI

Alphabet Inc Portfolio holdings

AUM $4.02B
1-Year Est. Return 215.74%
This Fund
S&P 500
This Quarter Est. Return
+8.67%
1 Year Est. Return
+215.74%
3 Year Est. Return
+350.01%
5 Year Est. Return
+242.03%
10 Year Est. Return
+998.87%
AUM
$2.51B
AUM Growth
+$357M
Cap. Flow
+$268M
Cap. Flow %
10.68%
Top 10 Hldgs %
89.42%
Holding
45
New
1
Increased
3
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
GTLB icon
GitLab
GTLB
+$466M
2
FRSH icon
Freshworks
FRSH
+$172M
3
PRME icon
Prime Medicine
PRME
+$24.3M
4
GUTS icon
Fractyl Health
GUTS
+$5.58M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$238M
2
CRWD icon
CrowdStrike
CRWD
+$131M
3
OSCR icon
Oscar Health
OSCR
+$15.7M
4
NMRA icon
Neumora Therapeutics
NMRA
+$6.9M
5
IVVD icon
Invivyd
IVVD
+$4.77M

Sector Composition

Rank Sector Weight
1 Technology 62.03%
2 Healthcare 34.22%
3 Industrials 3.63%
4 Consumer Staples 0.12%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GTLB icon
1
GitLab
GTLB
$5.28B
$569M 22.64%
9,758,333
+7,111,021
+269% +$466M
CRWD icon
2
CrowdStrike
CRWD
$187B
$274M 10.91%
3,423,156
-1,711,576
-33% -$131M
DXCM icon
3
DexCom
DXCM
$27.6B
$248M 9.88%
1,790,773
-1,891,112
-51% -$238M
ARM icon
4
Arm
ARM
$278B
$245M 9.75%
1,960,784
– –
FRSH icon
5
Freshworks
FRSH
$2.84B
$225M 8.94%
12,336,643
+8,301,048
+206% +$172M
RVMD icon
6
Revolution Medicines
RVMD
$40.2B
$171M 6.8%
5,301,512
– –
VERV
7
DELISTED
Verve Therapeutics
VERV
$164M 6.52%
12,349,086
– –
PATH icon
8
UiPath
PATH
$5.62B
$159M 6.34%
7,034,337
– –
PRME icon
9
Prime Medicine
PRME
$533M
$105M 4.19%
15,062,498
+3,200,000
+27% +$24.3M
SNOW icon
10
Snowflake
SNOW
$92.9B
$86.6M 3.44%
535,604
– –
PL icon
11
Planet Labs
PL
$7.3B
$81.5M 3.24%
31,942,641
– –
SANA icon
12
Sana Biotechnology
SANA
$885M
$28.1M 1.12%
2,812,500
– –
IVVD icon
13
Invivyd
IVVD
$180M
$20.1M 0.8%
4,527,122
-1,153,663
-20% -$4.77M
LYEL icon
14
Lyell Immunopharma
LYEL
$309M
$13.1M 0.52%
293,256
– –
RLAY icon
15
Relay Therapeutics
RLAY
$4.02B
$13M 0.52%
1,568,753
– –
BEAM icon
16
Beam Therapeutics
BEAM
$2.58B
$10.6M 0.42%
321,604
– –
VERA icon
17
Vera Therapeutics
VERA
$2.54B
$10.4M 0.41%
241,264
-60,316
-20% -$2.15M
GLUE icon
18
Monte Rosa Therapeutics
GLUE
$1.92B
$10.3M 0.41%
1,464,015
– –
DM
19
DELISTED
Desktop Metal, Inc.
DM
$9.72M 0.39%
1,104,873
– –
TCRX icon
20
TScan Therapeutics
TCRX
$51.9M
$8.55M 0.34%
1,077,080
– –
ILMN icon
21
Illumina
ILMN
$29.4B
$7.34M 0.29%
54,967
– –
OSCR icon
22
Oscar Health
OSCR
$8.5B
$7.17M 0.29%
481,988
-1,147,099
-70% -$15.7M
DNTH icon
23
Dianthus Therapeutics
DNTH
$5.68B
$6.26M 0.25%
208,697
– –
GUTS icon
24
Fractyl Health
GUTS
$123M
$4.9M 0.2%
+662,584
New +$5.58M
RAPT
25
DELISTED
RAPT Therapeutics
RAPT
$4.85M 0.19%
67,534
– –
1
2

Similar funds

JSW
Journey Strategic Wealth Summit, New Jersey $4.03B AUM 33.12% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.04B AUM 1.15% 1-Year Est. Return
MAM
Martingale Asset Management Boston, Massachusetts $3.99B AUM 22.65% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return
ICP
Ilex Capital Partners London, United Kingdom $4.06B AUM 6.11% 1-Year Est. Return
CA
CSM Advisors Warrendale, Pennsylvania $4.07B AUM 29.62% 1-Year Est. Return
MGP
Metis Global Partners San Diego, California $4.07B AUM 30.82% 1-Year Est. Return

Alphabet Inc's Q1 2024 Portfolio in Review

As of Q1 2024, Alphabet Inc held 45 positions worth $2.51B, up 17% from $2.16B the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Alphabet Inc deployed $268M of net new capital in Q1 2024, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Fractyl Health: 662,584 shares worth $4.9M.

By sector, the portfolio is most concentrated in Technology at 62% of assets, up from 47% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was DexCom, an estimated $238M trimmed.

  • Alphabet Inc's largest Q1 2024 buy was Fractyl Health: 662,584 shares worth $4.9M.
  • Alphabet Inc added most to GitLab in Q1 2024, an estimated $466M increase.
  • Alphabet Inc's biggest Q1 2024 reduction was DexCom, cutting an estimated $238M.
  • Alphabet Inc fully exited Neumora Therapeutics in Q1 2024, selling an estimated $6.9M.
  • Alphabet Inc's ten largest holdings make up 89% of its $2.51B portfolio in Q1 2024.
  • Alphabet Inc opened 1 new position and closed 2 in Q1 2024.
  • Alphabet Inc's portfolio value rose 17% quarter-over-quarter to $2.51B.

Based on Alphabet Inc's 13F filing for Q1 2024, filed 3 May 2024.